Haploidentical donor bone marrow transplantation (BMT) for advanced hematologic malignancy (HM) following non-myeloablative preparative therapy: Role of in vivo T-cell depletion with anti-thymocyte globulin or anti-CD2 monoclonal antibody therapy (MEDI-507). Conference

Spitzer, TR, McAfee, S, Sackstein, R et al. (2000). Haploidentical donor bone marrow transplantation (BMT) for advanced hematologic malignancy (HM) following non-myeloablative preparative therapy: Role of in vivo T-cell depletion with anti-thymocyte globulin or anti-CD2 monoclonal antibody therapy (MEDI-507). . BLOOD, 96(11), 841A-841A.

cited authors

  • Spitzer, TR; McAfee, S; Sackstein, R; Dey, B; Colby, C; Grossberg, H; Hope, J; Saidman, S; Preffer, F; Alexander, S; Sachs, DH; Sykes, M

sustainable development goals

authors

publication date

  • November 16, 2000

webpage

published in

keywords

  • Hematology
  • Life Sciences & Biomedicine
  • Science & Technology

publisher

  • AMER SOC HEMATOLOGY

start page

  • 841A

end page

  • 841A

volume

  • 96

issue

  • 11